Three speaker-program resolutions announced by DOJ since January 2025 show the pattern: Biohaven ($59.7 million), Gilead ($202 million), and Takeda ($13.67 million). The conduct described repeats: speaker pay, meals, and HCPs who attended the same program again. Each settlement covered conduct from years earlier, so a program’s record has to be complete long after it closes.
Read the source language. Most matters here are allegations resolved by settlement, with no finding of liability. Gilead’s resolution also included factual admissions described by DOJ.
The cases
| Announced | Company | Amount | What DOJ described | Conduct period | Rules that check it |
|---|---|---|---|---|---|
| Biohaven (now part of Pfizer) | $59.7M | Allegations: speaker honoraria, high-end meals, and repeat attendees (Nurtec ODT) | 2020–2022 | ||
| Gilead | $202M | Admissions: honoraria, meals, and travel for HCPs who spoke at or attended speaker events (HIV medicines) | 2011–2017 | ||
| Takeda | $13.67M | Allegations: speaker honoraria, high-end meals, and prescribers who attended multiple programs on the same topic (Trintellix); DOJ stated there was no determination of liability | 2014–2020 |
Broader context: DOJ reported more than $6.8 billion in False Claims Act settlements and judgments in fiscal year 2025.
What the patterns ask of the SOP
Each pattern maps to a rule in the client’s SOP: the attendance limit, the venue, meal, and alcohol rules, the honorarium cap, and approved materials presented by a trained speaker. The full mapping to OIG’s concerns, with a question for each, is in the operator’s guide.
Review your own records
Pick one closed program for each client. For every rule in that client’s SOP, check that the record shows who decided, when, and why. The settlements above were announced years after the conduct, so test a program that closed at least a year ago.
Then check the attendance. Each attendee should be one confirmed HCP record, with a signature or a reason for a late entry, and that HCP’s spend row should match what the program shows.
The public actions referenced in this article are cited for context. The companies involved are not Pharmagin customers. Pharmagin is software, not legal counsel; nothing here is legal advice.
Common questions
What did the Takeda settlement involve?
In May 2026, Takeda agreed to pay $13.67 million to resolve allegations about Trintellix speaker programs from 2014 to 2020: speaker honoraria, high-end meals, and prescribers who attended multiple programs on the same topic. DOJ stated these were allegations only, with no determination of liability.
What did Gilead admit?
DOJ described extensive factual admissions that Gilead paid honoraria, meals, and travel to HCPs who spoke at or attended its HIV speaker events, to encourage prescribing.